Welcome to our dedicated page for RVL Pharmaceuticals plc news (Ticker: RVLP), a resource for investors and traders seeking the latest updates and insights on RVL Pharmaceuticals plc stock.
RVL Pharmaceuticals plc (RVLP) drives innovation in specialty ophthalmology and neurology treatments, most notably through its groundbreaking product UPNEEQ® – the first FDA-approved non-surgical solution for acquired blepharoptosis. This page serves as the definitive source for official company announcements, financial disclosures, and therapeutic developments.
Investors and industry professionals will find timely updates on regulatory milestones, clinical advancements, and corporate strategy. Our curated news collection includes earnings reports, partnership announcements, and progress updates on neurology-focused therapies for conditions like multiple sclerosis and Parkinson's disease.
Key areas of coverage include UPNEEQ® market adoption, Osmodex® technology applications, and strategic shareholder initiatives. All content is sourced directly from RVL Pharmaceuticals' verified communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to RVLP's latest press releases and financial presentations. Check back regularly for updates on pharmaceutical innovations that combine clinical expertise with patient-centric solutions.
RVL Pharmaceuticals (RVLP) reported exceptional financial performance for 2022, with total revenues reaching $49.7 million, a 184% increase from 2021. The launch of UPNEEQ, the first FDA-approved solution for droopy eyelids, drove net product sales to $34.2 million, marking a remarkable 356% year-over-year growth. Fourth-quarter net product sales were $9.8 million, a 216% increase from the previous year. Despite losses from continuing operations totaling $(51.7) million, the company showed improvement in adjusted EBITDA losses. RVL is focusing on expanding UPNEEQ's market presence and developing its new e-commerce platform.
RVL Pharmaceuticals plc (Nasdaq: RVLP) announced a conference call to discuss its fourth quarter and full year 2022 financial results, scheduled for March 20, 2023, at 8:30 a.m. ET. The call will feature CEO Brian Markison and other executives providing updates on the company's product UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which treats acquired blepharoptosis in adults. The company is focused on the commercialization of UPNEEQ, the first FDA-approved non-surgical treatment for this condition. Participants can access the call via a toll-free number or through a webcast, with a replay available for two weeks afterward.
RVL Pharmaceuticals (RVLP) reported preliminary fourth quarter 2022 net product sales of UPNEEQ® at approximately $12.1 million, a 21% increase over the previous quarter, and total annual sales of $36.5 million, reflecting nearly 400% growth compared to 2021. By the end of Q4 2022, around 4,300 unique medical aesthetics practices had placed orders for the product. CEO Brian Markison expressed optimism about continued sales growth and the upcoming launch of an eCommerce platform.
The preliminary data remains subject to change and has not been audited.
RVL Pharmaceuticals plc (Nasdaq: RVLP) announced that CEO Brian Markison will participate in a panel and host 1x1 investor meetings at the Cantor Medical & Aesthetic Dermatology Conference in Miami, FL, on December 8, 2022, at 9:00 am ET. RVL specializes in UPNEEQ®, the first FDA-approved non-surgical treatment for acquired blepharoptosis. Investors can request meetings via corporateaccess@cantor.com.
RVL Pharmaceuticals (RVLP) reported third quarter 2022 net product sales of UPNEEQ at $10.0 million, a 19% increase from Q2 2022 and 355% year-over-year. The company anticipates fourth quarter sales to grow by 20%-40%, reaching $12-$14 million. Cumulative orders from unique medical aesthetics practices rose by 59% to approximately 3,500. Despite losses from continuing operations of $(14.4) million, this is an improvement from $(26.3) million in 2021. Cash and equivalents stood at $59.8 million against $75.0 million in debt obligations.
RVL Pharmaceuticals (Nasdaq: RVLP) is set to announce its Q3 2022 financial results and provide a commercial update on November 10, 2022, after market close. The company specializes in the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), the first FDA-approved non-surgical treatment for acquired blepharoptosis. A conference call will follow the announcement at 4:30 p.m. ET.
Management, including CEO Brian Markison, COO James Schaub, and Interim CFO Mike DePetris, will discuss the results and answer questions.
RVL Pharmaceuticals (Nasdaq: RVLP) announced preliminary third quarter 2022 net product sales of UPNEEQ at approximately $10.0 million, marking a 19% increase from Q2. Cumulative orders reached around 3,500 unique medical aesthetics practices, a 59% increase since Q2. The company anticipates fourth quarter sales growth of 20% to 40%, projecting sales between $12 million and $14 million. This growth reflects UPNEEQ's expanding market presence in the eyecare sector, indicating strong demand and potential market acceptance.
RVL Pharmaceuticals plc (Nasdaq: RVLP) announced that CEO Brian Markison will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 11:00 AM ET. The presentation will be available via webcast on the company's website. RVL will also participate in 1x1 investor meetings on the same day. The company specializes in UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), FDA-approved for treating acquired blepharoptosis in adults, marking the first non-surgical option for this condition.
Revision Skincare announced a strategic partnership with RVL Pharmaceuticals (Nasdaq: RVLP) on August 30, 2022. This collaboration aims to enhance access to aesthetic solutions, combining Revision Skincare's innovative products with RVL's UPNEEQ, the first FDA-approved eye drop for acquired ptosis. Both companies share a commitment to patient health and aesthetics, planning joint marketing efforts to address unmet needs in the market. This partnership is expected to broaden the consumer reach and leverage each company's strengths in the skincare and ocular aesthetic segments.
